Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Moderate Buy" from Analysts
MarketBeat
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, fi
NASDAQ:RLMD